Uncategorized

Read the latest overview of people coming and going from executive positions at biopharma companies that BioSpace covers.

As the Biden administration calls for more-expansive drug pricing controls, it’s important to reflect on how we’re arriving at expected outcomes.

Alongside the abrupt departure of Chinese biotech WuXi from BIO, Congress is rattling sabers over perceived national security implications of the U.S.’s R&D relationship with the country.

Avenzo’s founders, who led Turning Point through its $4.1 billion sale to BMS, want to in-license three clinical-stage oncology candidates by early 2026.

The clearance ends a three-year back-and-forth with the FDA to get the product to market.

Despite heavy lobbying, insurers failed to see MA rates improve in the final rule, which codified a 0.16% decrease to benchmark funding.

The transcatheter tricuspid valve repair device will compete against Edwards Lifesciences’ Evoque system.

Damages could shrink on appeal and Universal Health Services has malpractice insurance to cover some costs, but the for-profit’s exposure from the case could still amount to hundreds of millions of dollars.

El cáncer de piel tipo melanoma, conocido por su agresividad y alta tasa de mortalidad, ha sido objeto de intensas investigaciones en las últimas décadas. Estos esfuerzos han dado lugar a avances significativos que no solo mejoran nuestra comprensión de la enfermedad, sin …

Infutronix listed six issues that can cause the pumps to stop infusions and otherwise malfunction.